25,836 Shares in DaVita Inc. (NYSE:DVA) Purchased by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,836 shares of the company's stock, valued at approximately $3,864,000.

Several other hedge funds also recently modified their holdings of the stock. SBI Securities Co. Ltd. purchased a new position in shares of DaVita during the 4th quarter valued at $41,000. Quarry LP purchased a new position in DaVita in the 3rd quarter worth $60,000. Venturi Wealth Management LLC increased its stake in DaVita by 59.8% in the 4th quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after purchasing an additional 152 shares during the period. Versant Capital Management Inc raised its holdings in DaVita by 58.7% during the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company's stock valued at $68,000 after buying an additional 169 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock valued at $76,000 after acquiring an additional 131 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on DVA shares. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. StockNews.com lowered DaVita from a "buy" rating to a "hold" rating in a research note on Friday, March 21st. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Finally, Barclays lifted their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $166.33.

Remove Ads

DaVita Trading Down 1.5 %

Shares of NYSE DVA traded down $2.21 during mid-day trading on Friday, reaching $150.29. 614,947 shares of the company's stock were exchanged, compared to its average volume of 808,883. DaVita Inc. has a 52-week low of $125.64 and a 52-week high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company's 50-day moving average is $157.39 and its 200-day moving average is $157.55. The firm has a market capitalization of $12.02 billion, a price-to-earnings ratio of 13.99, a PEG ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.